Skeletal muscle pathology in Huntington's disease

Frontiers in Physiology

Volumn 5, Issue OCT, 2014, Pages

  Zielonka, Daniel ^a   Piotrowska, Izabela ^b   Marcinkowski, Jerzy T ^a   Mielcarek, Michal ^c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

Disease modifying treatment; Huntington's disease; Peripheral pathology; Skeletal muscle atrophy

Indexed keywords

BEZAFIBRATE; HUNTINGTIN; POLYGLUTAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BASAL GANGLION; BODY MASS; BRAIN CORTEX; CARDIOMYOPATHY; COGNITIVE DEFECT; CONTROLLED STUDY; HUNTINGTON CHOREA; MENTAL DISEASE; MOTOR DYSFUNCTION; MOTOR UNIT; MOUSE; MUSCLE ATROPHY; MUSCLE FUNCTION; MUSCLE HYPERTROPHY; NERVE DEGENERATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PHENOTYPE; SHORT SURVEY; SKELETAL MUSCLE; WEIGHT REDUCTION;

EID: 84908384280     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2014.00380     Document Type: Short Survey

References (49)

1. Bruneteau, G., Simonet, T., Bauche, S., Mandjee, N., Malfatti, E., Girard, E., et al. (2013). Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: potential role in reinnervation ability and disease progression. Brain 136, 2359-2368. doi: 10.1093/brain/awt164
2. Busse, M. E., Hughes, G., Wiles, C. M., and Rosser, A. E. (2008). Use of hand-held dynamometry in the evaluation of lower limb muscle strength in people with Huntington's disease. J. Neurol. 255, 1534-1540. doi: 10.1007/s00415-008-0964-x
3. Carter, R. J., Lione, L. A., Humby, T., Mangiarini, L., Mahal, A., Bates, G. P., et al. (1999). Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 19, 3248-3257.
4. Chaturvedi, R. K., Adhihetty, P., Shukla, S., Hennessy, T., Calingasan, N., Yang, L., et al. (2009). Impaired PGC-1alpha function in muscle in Huntington's disease. Hum. Mol. Genet. 18, 3048-3065. doi: 10.1093/hmg/ddp243
5. Ciammola, A., Sassone, J., Alberti, L., Meola, G., Mancinelli, E., Russo, M. A., et al. (2006). Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects. Cell Death Differ. 13, 2068-2078. doi: 10.1038/sj.cdd.4401967
6. Ciammola, A., Sassone, J., Sciacco, M., Mencacci, N. E., Ripolone, M., Bizzi, C., et al. (2011). Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington's disease. Mov. Disord. 26, 130-137. doi: 10.1002/mds.23258
7. Crook, Z. R., and Housman, D. (2011). Huntington's disease: can mice lead the way to treatment? Neuron 69, 423-435. doi: 10.1016/j.neuron.2010.12.035
8. Ehrnhoefer, D. E., Skotte, N. H., Ladha, S., Nguyen, Y. T., Qiu, X., Deng, Y., et al. (2014). p53 increases caspase-6 expression and activation in muscle tissue expressing mutant huntingtin. Hum. Mol. Genet. 23, 717-729. doi: 10.1093/hmg/ddt458
9. Fujimoto, M., Takaki, E., Hayashi, T., Kitaura, Y., Tanaka, Y., Inouye, S., et al. (2005). Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models. J. Biol. Chem. 280, 34908-34916. doi: 10.1074/jbc.M506288200
10. Gizatullina, Z. Z., Lindenberg, K. S., Harjes, P., Chen, Y., Kosinski, C. M., Landwehrmeyer, B. G., et al. (2006). Low stability of Huntington muscle mitochondria against Ca2+ in R6/2 mice. Ann. Neurol. 59, 407-411. doi: 10.1002/ana.20754
11. Gusella, J. F., MacDonald, M. E., Ambrose, C. M., and Duyao, M. P. (1993). Molecular genetics of Huntington's disease. Arch. Neurol. 50, 1157-1163. doi: 10.1001/archneur.1993.00540110037003
12. HDRG. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72, 971-83. doi: 10.1016/0092-8674(93)90585-E
13. Hoogeveen, A. T., Willemsen, R., Meyer, N., de Rooij, K. E., Roos, R. A., van Ommen, G. J., et al. (1993). Characterization and localization of the Huntington disease gene product. Hum. Mol. Genet. 2, 2069-2073. doi: 10.1093/hmg/2.12.2069
14. Johri, A., Calingasan, N. Y., Hennessey, T. M., Sharma, A., Yang, L., Wille, E., et al. (2012). Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Hum. Mol. Genet. 21, 1124-1137. doi: 10.1093/hmg/ddr541
15. Kosinski, C. M., Schlangen, C., Gellerich, F. N., Gizatullina, Z., Deschauer, M., Schiefer, J., et al. (2007). Myopathy as a first symptom of Huntington's disease in a Marathon runner. Mov. Disord. 22, 1637-1640. doi: 10.1002/mds.21550
16. Labbadia, J., and Morimoto, R. I. (2013). Huntington's disease: underlying molecular mechanisms and emerging concepts. Trends Biochem. Sci. 38, 378-385. doi: 10.1016/j.tibs.2013.05.003
17. Lee, C. Y., Cantle, J. P., and Yang, X. W. (2013). Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis. FEBS J. 18, 4382-4394. doi: 10.1111/febs.12418
18. Li, S. H., and Li, X. J. (2004). Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet. 20, 146-154. doi: 10.1016/j.tig.2004.01.008
19. Lin, J., Handschin, C., and Spiegelman, B. M. (2005). Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 1, 361-370. doi: 10.1016/j.cmet.2005.05.004
20. Lione, L. A., Carter, R. J., Hunt, M. J., Bates, G. P., Morton, A. J., and Dunnett, S. B. (1999). Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J. Neurosci. 19, 10428-10437.
21. Lodi, R., Schapira, A. H., Manners, D., Styles, P., Wood, N. W., Taylor, D. J., et al. (2000). Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann. Neurol. 48, 72-76. doi: 10.1002/1531-8249(200007)48:1<72::AID-ANA11>3.0.CO;2-I
22. Luthi-Carter, R., Hanson, S. A., Strand, A. D., Bergstrom, D. A., Chun, W., Peters, N. L., et al. (2002). Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet. 11, 1911-1926. doi: 10.1093/hmg/11.17.1911
23. Mielcarek, M., Inuabasi, L., Bondulich, M. K., Muller, T., Osborne, G. F., Franklin, S. A., et al. (2014). Dysfunction of the CNS-Heart Axis in Mouse Models of Huntington's Disease. PLoS Genet. 10:e1004550. doi: 10.1371/journal.pgen.1004550
24. Mielcarek, M., Landles, C., Weiss, A., Bradaia, A., Seredenina, T., Inuabasi, L., et al. (2013b). HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biol. 11:e1001717. doi: 10.1371/journal.pbio.1001717
25. Mielcarek, M., Seredenina, T., Stokes, M. P., Osborne, G. F., Landles, C., Inuabasi, L., et al. (2013a). HDAC4 does not act as a protein deacetylase in the postnatal murine brain in vivo. PLoS ONE 8:e80849. doi: 10.1371/journal.pone.0080849
26. Moffitt, H., McPhail, G. D., Woodman, B., Hobbs, C., and Bates, G. P. (2009). Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease. PLoS ONE 4:e8025. doi: 10.1371/journal.pone.0008025
27. Murphy, K. P., Carter, R. J., Lione, L. A., Mangiarini, L., Mahal, A., Bates, G. P., et al. (2000). Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J. Neurosci. 20, 5115-5123.
28. Novak, M. J., and Tabrizi, S. J. (2010). Huntington's disease. BMJ 340:c3109. doi: 10.1136/bmj.c3109
29. Orth, M., Cooper, J. M., Bates, G. P., and Schapira, A. H. (2003). Inclusion formation in Huntington's disease R6/2 mouse muscle cultures. J. Neurochem. 87, 1-6. doi: 10.1046/j.1471-4159.2003.02009.x
30. Quintanilla, R. A., and Johnson, G. V. W. (2009). Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease. Brain Res. Bull. 80, 242-247. doi: 10.1016/j.brainresbull.2009.07.010
31. Rattray, I., Smith, E., Gale, R., Matsumoto, K., Bates, G. P., and Modo, M. (2013). Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/2 mouse model of HD. PLoS ONE 8:e60012. doi: 10.1371/journal.pone.0060012
32. Reddy, P. H. (2014). Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fission. Drug Discov. Today 19, 951-955. doi: 10.1016/j.drudis.2014.03.020
33. Ribchester, R. R., Thomson, D., Wood, N. I., Hinks, T., Gillingwater, T. H., Wishart, T. M., et al. (2004). Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur. J. Neurosci. 20, 3092-3114. doi: 10.1111/j.1460-9568.2004.03783.x
34. Rozas, J. L., Gomez-Sanchez, L., Tomas-Zapico, C., Lucas, J. J., and Fernandez-Chacon, R. (2011). Increased neurotransmitter release at the neuromuscular junction in a mouse model of polyglutamine disease. J. neurosci. 31, 1106-1113. doi: 10.1523/JNEUROSCI.2011-10.2011
35. Saft, C., Zange, J., Andrich, J., Muller, K., Lindenberg, K., Landwehrmeyer, B., et al. (2005). Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov. Disord. 20, 674-679. doi: 10.1002/mds.20373
36. Sassone, J., Colciago, C., Cislaghi, G., Silani, V., and Ciammola, A. (2009). Huntington's disease: the current state of research with peripheral tissues. Exp. Neurol. 219, 385-397. doi: 10.1016/j.expneurol.2009.05.012
37. Sathasivam, K., Hobbs, C., Turmaine, M., Mangiarini, L., Mahal, A., Bertaux, F., et al. (1999). Formation of polyglutamine inclusions in non-CNS tissue. Hum. Mol. Genet. 8, 813-822. doi: 10.1093/hmg/8.5.813
38. Sathasivam, K., Neueder, A., Gipson, T. A., Landles, C., Benjamin, A. C., Bondulich, M. K., et al. (2013). Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc. Natl. Acad. Sci. U.S.A. 110, 2366-2370. doi: 10.1073/pnas.1221891110
39. She, P., Zhang, Z., Marchionini, D., Diaz, W. C., Jetton, T. J., Kimball, S. R., et al. (2011). Molecular characterization of skeletal muscle atrophy in the R6/2 mouse model of Huntington's disease. Am. J. Physiol. Endocrinol. Metab. 301, E49-E61. doi: 10.1152/ajpendo.00630.2010
40. Strand, A. D., Aragaki, A. K., Shaw, D., Bird, T., Holton, J., Turner, C., et al. (2005). Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum. Mol. Genet. 14, 1863-1876. doi: 10.1093/hmg/ddi192
41. Strong, T. V., Tagle, D. A., Valdes, J. M., Elmer, L. W., Boehm, K., Swaroop, M., et al. (1993). Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat. Genet. 5, 259-265. doi: 10.1038/ng1193-259
42. Trottier, Y., Devys, D., Imbert, G., Saudou, F., An, I., Lutz, Y., et al. (1995). Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat. Genet. 10, 104-110. doi: 10.1038/ng0595-104
43. van der Burg, J. M., Bjorkqvist, M., and Brundin, P. (2009). Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol. 8, 765-774. doi: 10.1016/S1474-4422(09)70178-4
44. Vonsattel, J. P., and DiFiglia, M. (1998). Huntington disease. J. Neuropathol. Exp. Neurol. 57, 369-384. doi: 10.1097/00005072-199805000-00001
45. Wade, A., Jacobs, P., and Morton, A. J. (2008). Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation. Brain Res. 1188, 61-68. doi: 10.1016/j.brainres.2007.06.059
46. Walker, F. O. (2007). Huntington's disease. Lancet 369, 218-228. doi: 10.1016/S0140-6736(07)60111-1
47. Waters, C. W., Varuzhanyan, G., Talmadge, R. J., and Voss, A. A. (2013). Huntington disease skeletal muscle is hyperexcitable owing to chloride and potassium channel dysfunction. Proc. Natl. Acad. Sci. U.S.A. 110, 9160-9165. doi: 10.1073/pnas.1220068110
48. Zeitlin, S., Liu, J. P., Chapman, D. L., Papaioannou, V. E., and Efstratiadis, A. (1995). Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet. 11, 155-163. doi: 10.1038/ng1095-155
49. Zielonka, D., Piotrowska, I., and Mielcarek, M. (2014). Cardiac Dysfunction in Huntington's Disease. Exp. Clin. Cardiol. 20, 2547-2554. Available online at: http://cardiologyacademicpress.com/soap/pdf/delme_1788_53e3f6e3313354.90986595.pdf